Mike Westby
Publications by Year
Research Areas
HIV Research and Treatment, HIV/AIDS drug development and treatment, Immune Cell Function and Interaction, Hepatitis C virus research, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity(2005)1,144 cited
- → Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection(2008)359 cited
- → Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry(2006)346 cited
- → Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir(2006)331 cited
- → The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques(1996)329 cited
- → Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection(2010)265 cited
- → Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase Multimerization(2012)171 cited
- → A Double‐Blind, Placebo‐Controlled Trial of Maraviroc in Treatment‐Experienced Patients Infected with Non‐R5 HIV‐1(2009)133 cited
- → CCR5 Antagonists: Host-Targeted Antivirals for the Treatment of HIV Infection(2005)123 cited
- → Loss of CD4+T Cell Proliferative Ability but Not Loss of Human Immunodeficiency Virus Type 1 Specificity Equates with Progression to Disease(2000)121 cited